Statins

For statin-intolerant patients, what's next?

For statin-intolerant patients, what's next?

By

Despite their blockbuster status and distinction as the world's most widely prescribed class of drugs, statins may not be the best option for all patients with elevated low density lipoprotein (LDL) cholesterol levels.

Five things for pharma marketers to know: Wednesday, December 2, 2015

Five things for pharma marketers to know: Wednesday, December 2, 2015

By

Negative news coverage of statins may lead people to stop taking their medication; second patient dies in Zafgen obesity drug trial; Gilead defends pricing

Five things for pharma marketers to know: Tuesday, November 10, 2015

Five things for pharma marketers to know: Tuesday, November 10, 2015

By

Aggressive treatment of blood pressure reduces deaths; AstraZeneca's experimental lupus drug cut disease activity in trial; Sophiris Bio reports results for enlarged prostate drug

OPINION

Healthcare Marketers: The Future is Personal

Email Newsletters